Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study

Background: Primary lack or secondary loss of response to therapy with infliximab is a significant problem. This study aimed to evaluate the response to treatment in patients with Crohn’s disease (CD) and ulcerative colitis (UC) achieving therapeutic and sub-therapeutic trough levels of biosimilar i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Pękala, Rafał Filip
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	CT-P13 biosimilar anti-TNF treatment response treatment monitoring Medicine R
Acceso en línea:	https://doaj.org/article/6694919a01ba43bca702d565aa166459
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6694919a01ba43bca702d565aa166459
record_format	dspace
spelling	oai:doaj.org-article:6694919a01ba43bca702d565aa1664592021-11-25T18:01:40ZLevels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study10.3390/jcm102253112077-0383https://doaj.org/article/6694919a01ba43bca702d565aa1664592021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5311https://doaj.org/toc/2077-0383Background: Primary lack or secondary loss of response to therapy with infliximab is a significant problem. This study aimed to evaluate the response to treatment in patients with Crohn’s disease (CD) and ulcerative colitis (UC) achieving therapeutic and sub-therapeutic trough levels of biosimilar infliximab (CT-P13). Results: A total of 65 patients (32 with CD and 33 with UC) were recruited. The overall response rate in both CD and UC patients exceeded 80%. There were no significant differences in treatment response and CT-P13 levels for patients with CD or UC. We did not find significant differences in the percentage of patients achieving drug levels of 3 μg/mL at week 6, 10, or 12; a significant decrease was observed at week 14. Up to 55.5% of patients with CD and 64.3% of patients with UC with sub-therapeutic CT-P13 levels at week 14 primarily responded to treatment. Conclusions: Intermediate measurements of drug levels at weeks 10 and 12 did not capture any pronounced decrease in infliximab concentrations below therapeutic levels in either group, thus suggesting no clinical usefulness. A significant percentage of patients primarily responded to treatment despite sub-therapeutic drug levels after the induction phase.Anna PękalaRafał FilipMDPI AGarticleCT-P13biosimilaranti-TNFtreatment responsetreatment monitoringMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5311, p 5311 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CT-P13 biosimilar anti-TNF treatment response treatment monitoring Medicine R
spellingShingle	CT-P13 biosimilar anti-TNF treatment response treatment monitoring Medicine R Anna Pękala Rafał Filip Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
description	Background: Primary lack or secondary loss of response to therapy with infliximab is a significant problem. This study aimed to evaluate the response to treatment in patients with Crohn’s disease (CD) and ulcerative colitis (UC) achieving therapeutic and sub-therapeutic trough levels of biosimilar infliximab (CT-P13). Results: A total of 65 patients (32 with CD and 33 with UC) were recruited. The overall response rate in both CD and UC patients exceeded 80%. There were no significant differences in treatment response and CT-P13 levels for patients with CD or UC. We did not find significant differences in the percentage of patients achieving drug levels of 3 μg/mL at week 6, 10, or 12; a significant decrease was observed at week 14. Up to 55.5% of patients with CD and 64.3% of patients with UC with sub-therapeutic CT-P13 levels at week 14 primarily responded to treatment. Conclusions: Intermediate measurements of drug levels at weeks 10 and 12 did not capture any pronounced decrease in infliximab concentrations below therapeutic levels in either group, thus suggesting no clinical usefulness. A significant percentage of patients primarily responded to treatment despite sub-therapeutic drug levels after the induction phase.
format	article
author	Anna Pękala Rafał Filip
author_facet	Anna Pękala Rafał Filip
author_sort	Anna Pękala
title	Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
title_short	Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
title_full	Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
title_fullStr	Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
title_full_unstemmed	Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
title_sort	levels of biosimilar infliximab during and after induction treatment in crohn’s disease and ulcerative colitis—a prospective polish population study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6694919a01ba43bca702d565aa166459
work_keys_str_mv	AT annapekala levelsofbiosimilarinfliximabduringandafterinductiontreatmentincrohnsdiseaseandulcerativecolitisaprospectivepolishpopulationstudy AT rafałfilip levelsofbiosimilarinfliximabduringandafterinductiontreatmentincrohnsdiseaseandulcerativecolitisaprospectivepolishpopulationstudy
_version_	1718411747363127296

Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study

Ejemplares similares